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BACKGROUND: Previous prospective studies have found an association between prolactin (PRL) levels and increased risk of breast
cancer. Using data from a population-based breast cancer case–control study conducted in two cities in Poland (2000–2003),
we examined the association of PRL levels with breast cancer risk factors among controls and with tumour characteristics among
the cases.
METHODS: We analysed PRL serum levels among 773 controls without breast cancer matched on age and residence to 776 invasive
breast cancer cases with available pretreatment serum. Tumours were centrally reviewed and prepared as tissue microarrays for
immunohistochemical analysis. Breast cancer risk factors, assessed by interview, were related to serum PRL levels among controls
using analysis of variance. Mean serum PRL levels by tumour characteristics are reported. These associations also were evaluated
using polytomous logistic regression.
RESULTS: Prolactin levels were associated with nulliparity in premenopausal (P¼0.05) but not in postmenopausal women. Associations
in postmenopausal women included an inverse association with increasing body mass index (P¼0.0008) and direct association with
use of recent/current hormone therapy (P¼0.0006). In case-only analyses, higher PRL levels were more strongly associated with
lobular compared with ductal carcinoma among postmenopausal women (P¼0.02). Levels were not different
by tumour size, grade, node involvement or oestrogen receptor, progesterone receptor, or human epidermal growth factor
receptor 2 status.
CONCLUSIONS: Our analysis demonstrates that PRL levels are higher among premenopausal nulliparous as compared with parous
women. Among postmenopausal women, levels were higher among hormone users and lower among obese women. These results
may have value in understanding the mechanisms underlying several breast cancer risk factor associations.
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Prolactin (PRL) is a peptide hormone implicated in growth and
differentiation of breast epithelial cells (Das and Vonderhaar, 1997;
Maus et al, 1999; Vonderhaar, 1999; Clevenger et al, 2003). A
recent analysis of women from the Nurses’ Health Study (NHS) I
and II found that higher PRL levels were associated with breast
cancer risk, irrespective of menopausal status (RR¼1.3, 95%
confidence interval (CI) 1.1–1.6, Phet¼0.95) (Tworoger et al,
2007a). Previous, smaller case–control and prospective studies
(12–71 cases) have generated mixed results regarding the
association of PRL levels with breast cancer (Clevenger et al, 2003).
Cumulative data have shown parous women to have 15–50%
lower PRL levels than nulliparous women, with the majority of this
decrease following the first full-term pregnancy (Musey et al, 1987;
Wang et al, 1988; Ingram et al, 1990; Eliassen et al, 2007). The
associations of PRL levels with other known breast cancer risk
factors, including: age at menarche and first birth, benign breast
disease, and adult body weight, have mostly been null for both
pre- and postmenopausal women, even after adjusting for parity
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Eliassen et al, 2007; Su et al, 2009).
Conclusions regarding the associations of PRL with breast
cancer risk factors and tumour characteristics are largely based on
a small number of studies and, in some cases, small populations.
Accordingly, further assessment of risk related to PRL levels
by patient and tumour characteristics is needed. Using a large
population-based case–control study conducted in Poland, we
explored the association of PRL levels with known breast cancer
risk factors in both pre- and postmenopausal women in our
control population. We also examined associations of serum PRL
levels with tumour characteristics among the incident cases
of breast cancer.
MATERIALS AND METHODS
Details regarding the population and design of the Polish case–
control study have been reported elsewhere (Garcia-Closas et al,
2006). Subjects provided written informed consent and the study
protocol was approved by ethical boards in Poland and the United
States. Briefly, eligible cases were women ages 20–74 years with
pathologically confirmed breast cancer living in Warsaw or Lodz,
Poland and diagnosed from 2000 to 2003. The Polish Electronic
System, a database with demographic information from all
residents of Poland, was used to randomly select controls, defined
as women without breast cancer, frequency matched to cases on
city and age in 5-year categories. In total, 79% of eligible cases
(2386) and 69% of eligible controls (2502) consented to participate
in an interview regarding breast cancer risk factors. Of these
women, 84% of cases and 92% of controls agreeing to the interview
provided blood samples. Paraffin-embedded tumour tissue was
collected from 87% of cases.
Of 2386 eligible cases with questionnaire data, we selected the
subset with invasive cancer tissue prepared as tissue microarrays
(TMAs) (N¼1477). Serum samples were available from 1155
of these women. We excluded women treated before collection of
blood (n¼353) or tumour tissue (n¼23), resulting in 779 cases
for PRL serum analyses. Controls were matched to cases on
menopausal status, age (in 5-year increments), time of day of
blood draw (within 2h), study site, and, for premenopausal
women, day in menstrual cycle (±2 days).
Prolactin was measured by Quest Diagnostics (San Juan
Capistrano, CA, USA) using an immunoassay and concentrations
calculated by the ADVIA Centaur instrument (Bayer HealthCare,
Tarrytown, NY, USA), which was calibrated with known PRL
concentrations. Approximately 3% of samples that included low,
medium and high levels of PRL were retested in masked fashion to
assess intra- and interbatch variation. The overall coefficient of
variation for the PRL serum assay was o5% and the intraclass
correlation coefficient was 499%.
Histopathologic features including histology, grade, tumour
size, and axillary lymph node metastases were assessed using
surgical pathology reports. Tumour features were independently
evaluated by the study pathologist (MES). Results for immuno-
histochemical stains for oestrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2
(HER2) from the invasive cancers, prepared as TMAs with
duplicate representation as 0.6-mm diameter cores (Beecher
Instruments, Silver Spring, MD, USA), were determined as
reported previously (Sherman et al, 2007; Yang et al, 2007a,b).
Statistical analysis
Associations between subjects’ demographic and breast cancer risk
factors and serum PRL levels were assessed using T-test
(continuous) and w
2 analyses (categorical). Analyses were based
on natural log transformation of serum PRL levels. The association
of PRL concentrations with known risk factors was evaluated among
controls using analysis of variance. Details of the entire Poland breast
cancer case–control study population with questionnaire data have
been reported previously (Garcia-Closas et al, 2006).
To determine if serum PRL levels varied by important tumour
characteristics, we initially performed polytomous logistic regres-
sion to estimate odds ratios (OR) and 95% CI for PRL serum levels
with the relevant tumour characteristics as the outcome variables.
The final models adjusted for the following variables: time of blood
collection in 2-h categories, years of education, age at menarche
(p12, 13, 14, 15, and X16), age at menopause (o45, 45–49, and
X50–54), number of full-term births (0, 1, 2, or 3þ), age at first
full-term birth (o20, 20–24, 25–29, and X30), family history of
breast cancer among first-degree relatives, previous breast disease
(history of a benign breast biopsy 1 year before date of diagnosis
for cases and date of interview for controls), body mass index
(BMI) (o25, 25–29.9, and X30kgm
–2), age in 5-year categories,
and study site. For premenopausal women, the additional
matching variable of menstrual status was also adjusted for in
models. For postmenopausal women, models were also adjusted
for oral hormone replacement therapy (HRT) use (current/recent
use, past use, and ever used oestrogens or combined oestrogen/
progestin). Never users of oral HRT were those individuals who
used oral HRT for 1 month or less and, among users, current/
recent users were those for whom it had been 2 years or less since
last use and past users were those for whom the last use was 42
years ago. P-values to test for heterogeneity of ORs between
tumour characteristics were calculated using logistic regression
analyses restricted to cases with the relevant tumour characteristic
as the outcome and PRL serum hormone levels as the explanatory
variable. Mean serum PRL levels across important tumour
characteristics are reported to illustrate the relationship between
serum PRL levels and breast cancer histology.
In Supplementary Table 2, we report the associations of breast
cancer; with PRL levels, recognising the limitation that blood
measurements among patients may reflect disease effects or acute
stress responses. For these reasons, this analysis was limited to
individuals who had PRL levels within the normal range (i.e.,
p30ngml
–1), which excluded 4% (n¼19) of the premenopausal
population and 3% (n¼35) of the postmenopausal from the
analysis. PRL levels were significantly different between premeno-
pausal and postmenopausal controls. Therefore, separate quartiles
were established for pre- and postmenopausal women using the
distributions from the control population. For premenopausal
women the quartiles were p7.70, 7.71–10.20, 10.21–15.00, and
415.00ngml
–1. For postmenopausal women the quartiles were
p5.30, 5.31–6.70, 6.71–8.40, and 48.40ngml
–1. To estimate the
association between PRL serum levels and breast cancer risk, we
used conditional logistic regression models separately for pre- and
postmenopausal women, as described above for the analysis with
tumour characteristics, to compute OR and 95% CIs. Statistical
significance was defined as two-sided Po0.05 and all analyses were
completed with SAS (version 9.0, SAS Institute, Inc., Cary, NC,
USA) or STATA (version 9.0, STATA Corporation, College Station,
TX, USA) software.
RESULTS
Characteristics of study population
The study population consisted of 230 premenopausal and 543
postmenopausal breast cancer cases and an equal number of
matched controls. The mean age was approximately 45 (±5.3)
years old for premenopausal women and 61 (±7.7) years old for
postmenopausal women. With respect to breast cancer risk factors
and tumour characteristics, the distributions for the population
selected for the analyses presented herein (data not shown) did not
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control parent population (Garcia-Closas et al, 2006; Yang et al,
2007a). Means and frequencies for several breast cancer risk
factors are presented in Supplementary Table 1.
PRL and associations with risk factors among controls
in pre- and postmenopausal women
The association of PRL levels with established breast cancer risk
factors was examined among controls. Geometric mean PRL levels
were 10.9ngml
–1 in premenopausal controls and 7.0ngml
–1
in postmenopausal controls (Table 1). Among premenopausal
women, nulliparous women had marginally significantly higher
levels of PRL than parous women (mean 13.67 and 10.67ngml
–1,
respectively, P¼0.05) (Table 1). Other comparisons of strata for
menstrual and reproductive factors, personal history of benign
breast disease and family history were not related to signi-
ficant differences in PRL levels. Among postmenopausal women,
increasing BMI was associated with lower PRL levels (P¼0.0008).
In separate analyses of height and current weight, height was
positively associated (P¼0.04) and current weight was inversely
associated (P¼0.01) with serum PRL levels in postmenopausal
women (data not shown), suggesting that the association with
current weight is the dominant factor in the inverse association of
PRL levels with BMI.
With regard to oral contraceptive use, this population included
only 10 current and 28 former premenopausal oral contraceptive
users, precluding a meaningful analysis of the relationship of use
to PRL levels. Among postmenopausal controls, women currently
using HRT had significantly higher PRL levels than never or
Table 1 Established breast cancer risk factors and PRL serum levels among 773 population controls in the Polish Breast Cancer Study
Premenopausal N¼230 Postmenopausal N¼543
N
Geometric mean
PRL (ngml
–1) s.d. P-value N
Geometric mean
PRL (ngml
–1) s.d. P-value
Overall geometric mean PRL 230 10.90 1.68 543 7.00 1.74
Parity
Nulliparous 19 13.67 1.58 59 7.19 1.66
Parous 211 10.67 1.68 0.05
a 484 6.97 1.61 0.63
a
Age at menarche
p12 49 11.57 1.69 118 7.12 1.58
13 52 11.08 1.74 122 7.51 1.67
14 76 10.78 1.52 146 6.88 1.54
15 21 10.67 1.81 57 6.60 1.66
X16 29 9.43 1.84 0.56
b 94 6.50 1.62 0.19
b
No. of full-term births
Nulliparous 19 13.67 1.58 59 7.19 1.66
1 73 10.35 1.71 176 7.24 1.69
2 109 11.09 1.67 225 6.90 1.55
X3 29 9.98 1.58 0.15
b 83 6.57 1.59 0.43
b
Age at first full-term birth among parous women
p20 35 12.04 1.59 144 6.72 1.64
20–24 107 10.59 1.68 234 7.12 1.59
25–29 65 11.14 1.68 123 7.10 1.58
X30 23 9.96 1.81 0.3
b 42 7.23 1.77 0.24
b
Family history of breast cancer in first-degree relatives
No 220 10.86 1.68 506 6.96 1.76
Yes 10 11.66 1.77 0.67
a 37 7.45 1.49 0.40
a
History of benign breast disease
No 210 10.86 1.69 500 6.93 1.63
Yes 17 10.93 1.58 0.78
a 38 7.66 1.47 0.22
a
Current BMI (kgm
–2)
o25 118 10.99 1.71 165 7.80 1.77
25–o30 69 10.00 1.67 189 7.13 1.59
X30 42 12.14 1.59 0.15
b 188 6.22 1.46 0.0008
b
Age at menopause among postmenopausal women
o45 91 7.24 1.65
45–49 185 6.82 1.60
X50 266 6.37 1.62 0.80
b
Hormone therapy among postmenopausal
Never 422 6.73 1.62
Current/recent use 31 10.37 1.67
Past use 29 7.99 1.44
Ever used oestrogen or progesterone alone 26 7.09 1.44 0.0006
b
Abbreviations: ANOVA¼analysis of variance; BMI¼body mass index; PRL¼prolactin.
aP-values from t-test.
bP-values from ANOVA.
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HRT, the associations of serum PRL levels with BMI and HRT were
still significant (P¼0.0036 and P¼0.0028, respectively).
PRL levels and tumour characteristics in pre- and
postmenopausal women
In Supplementary Table 2, we report the association of PRL levels
with risk of breast cancer. Among postmenopausal women, higher
PRL levels were associated with increased risk of breast cancer
(OR¼1.76, 95% CI: 1.21–2.57, P¼0.003) when comparing the
highest with the lowest PRL quartile and, among premenopausal
women, PRL levels were not associated with increased breast
cancer risk.
We further evaluated the association of PRL levels with clinically
important tumour characteristics among cases (Table 2). In
postmenopausal women, lobular histology was associated with
higher levels of PRL than ductal histology (P¼0.02, Table 2);
removing HRT users from the analysis yielded similar conclusions
(P¼0.03). This difference in PRL levels translated into a stronger
risk association for lobular (OR¼3.04, 95% CI: 1.81–5.91) than
ductal (OR¼1.62, 95% CI: 1.18–2.23) tumours. No other
significant differences in PRL levels were noted across the tumour
characteristics of tumour grade, size, node involvement, and ER,
PR, or HER2 expression.
DISCUSSION
Our analysis of serum PRL levels among population-based controls
in the Polish study demonstrated significant relationships with
three established breast cancer risk factors: nulliparity, among
premenopausal women, and HRT and BMI among postmeno-
pausal women. Consistent with previous reports, we found that
PRL levels among parous premenopausal women were lower than
those among nulliparous women (Musey et al, 1987; Eliassen et al,
2007). In addition, among premenopausal parous women, levels
declined slightly with increasing parity. However, we did not find
an association between parity and PRL concentrations among
postmenopausal, which contrasts with some reports (Wang et al,
1988; Eliassen et al, 2007). Lowered PRL levels have been suggested
as one of several possible mechanisms that mediate this risk.
In this study, PRL levels were inversely associated with BMI
among postmenopausal women, whereas other analyses have
shown null (Kwa et al, 1976; Tworoger et al, 2007b; Su et al, 2009)
or positive associations (Wang et al, 1988; McTiernan et al, 2006).
Postmenopausal obesity is associated with higher circulating
oestrogen levels and increased breast cancer risk in many studies
(Key et al, 2001). Given that the PRL gene contains an oestrogen
response element and that in vitro oestrogen upregulates expression
of PRL (Duan et al, 2008), our inverse association is unexpected.
However, in previous analyses from this study, postmenopausal
obesity was associated only with larger tumours, rather than breast
Table 2 Geometric mean PRL serum levels stratified by clinically important tumour characteristics in the Polish Breast Cancer Study
Premenopausal Postmenopausal
N
Geometric mean
PRL (ngml
–1) s.d. P-value N
Geometric mean
PRL (ngml
–1) s.d. P-value
Histological type N¼751
Ductal 194 11.02 1.91 425 8.24 1.82
Lobular 30 12.14 1.44 0.23
a 102 9.82 2.03 0.02
a
Tumour size N¼766
p2cm 121 10.98 1.81 280 8.56 1.91
42cm 106 11.33 1.89 0.70
a 259 8.43 1.82 0.77
a
Tumour grade N¼667
Well/moderately differentiated 124 10.96 1.86 261 8.75 1.98
Poorly differentiated 85 11.16 1.86 0.84
a 201 8.57 1.79 0.73
a
Axillary node metastasis N¼755
Negative 122 11.20 1.95 335 8.34 1.83
Positive 103 11.24 1.72 0.97
a 195 8.66 1.92 0.50
a
ER N¼760
Negative 83 11.53 1.92 164 8.44 1.64
Positive 144 10.92 1.80 0.52
a 369 8.51 1.96 0.87
a
PR N¼762
Negative 80 10.39 1.88 279 8.51 1.83
Positive 148 11.60 1.82 0.19
a 255 8.47 1.91 0.87
a
ER/PR N¼759
ER+ PR+ 121 11.41 1.83 230 8.41 1.95
ER+PR  23 8.67 1.56 138 8.73 1.99
ER PR+ 26 12.38 1.81 25 8.98 7.54
ER PR  57 11.17 1.97 0.19
b 139 8.35 1.66 0.89
b
ER/PR/HER2 N¼752
ER+ or PR+ and HER2  166 11.25 1.81 381 8.59 1.95
ER+ or PR+ and HER2+ 5 8.14 1.71 12 7.52 1.74
ER  and PR  and HER2+ 12 10.14 1.77 38 8.61 1.8
ER  and PR  and HER2  45 11.35 2.04 0.64
b 93 8.28 1.62 0.87
b
Abbreviations: ANOVA¼analysis of variance; ER¼oestrogen receptor; HER2¼human epidermal growth factor receptor 2; PR¼progesterone receptor; PRL¼prolactin.
aP-values from t-test.
bP-values from ANOVA.
Associations of prolactin with breast cancer
JM Faupel-Badger et al
1100
British Journal of Cancer (2010) 103(7), 1097–1102 & 2010 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
ycancer overall (Garcia-Closas et al, 2006), so the subject requires
further investigation, ideally by considering distribution of adiposity
and concurrent measurements of serum oestrogens.
Although there have been reports demonstrating a positive
association of oral contraceptive use with PRL levels (Mishell et al,
1977; Scott et al, 1978; Clevenger et al, 2003), the data regarding
HRT are largely null (Castelo-Branco et al, 1995; Foth and Romer,
1997; Schlegel et al, 1999; Molitch, 2008). In our population, use of
both oral contraceptives and HRT were uncommon compared with
the United States. Nonetheless, recent/current HRT in the Polish
study was significantly associated with higher PRL levels in
postmenopausal women. Mutual adjustment of BMI and HRT did
not alter these interpretations substantively; both lower BMI and
HRT remained related to PRL concentrations. However, these
findings need careful interpretation as analyses were based on
small numbers of users.
Previous data have suggested that a positive family history of
breast cancer may be related to higher PRL levels, especially
among premenopausal women (Hankinson et al, 1995; Clevenger
et al, 2003; Eliassen et al, 2007). Similarly, we observed increased
risk related to increased levels of PRL among women with a family
history of breast cancer, but women with a positive family history
were relatively uncommon in this data set and results were not
statistically significant. Associations of PRL levels with benign
breast disease have been mixed and may depend on the particular
underlying pathologic condition leading to the development
of benign breast disease (Courtillot et al, 2005). We did not find
an association in Poland, but screening was less common than in
some other populations.
In addition, we examined the association of serum PRL levels
with tumour characteristics. We did not find significant difference
in geometric mean PRL levels by either tumour size or the
presence of lymph node metastases, suggesting that PRL levels may
not be related to time of clinical diagnosis. In this population, we
did identify a stronger relationship between high PRL levels and
postmenopausal invasive lobular carcinoma. This finding is
interesting and in contrast to previous reports in which no hetero-
geneity between invasive ductal and lobular cancers was detected
(Tworoger et al, 2007a). Some previous reports have suggested a
relationship between HRT and risk of lobular cancer (Li et al,
2008). Our finding of the association of higher PRL levels with
invasive lobular carcinoma was independent of HRT use.
Prolactin levels were not related to ER, PR, or HER2 status.
These data did not replicate the finding from NHS I and II where
the association with PRL was stronger among ERþ/PRþ tumours
(Tworoger et al, 2007a). Our study was truncated at age 74 years
and in a largely unscreened population; therefore, the character-
istics of our postmenopausal ERþ/PRþ cancers may have
differed from the NHS. Apart from this analysis, knowledge about
relationships of PRL levels and HER2 status are limited and further
studies are necessary.
The analyses presented herein have some limitations. Notably,
our case–control results must be interpreted with caution as PRL
is a stress hormone and we cannot exclude that the relationship
with breast cancer was influenced by a stress responses (Freeman
et al, 2000). In addition, breast tumour cells have been shown to
synthesise and secrete PRL in cell culture models (Ginsburg and
Vonderhaar, 1995). If PRL levels were affected by tumours or
patient stresses, our case–control estimates might be inflated;
however, our case–control associations are generally similar to
those found in NHS (Tworoger et al, 2007a).
In this study, PRL also was measured by an immunoassay that
does not discriminate between PRL isoforms, some of which are
reported to have varying biological activity (Freeman et al, 2000).
Regardless, this immunoassay is a widely accepted method
for measuring PRL in clinical and epidemiology studies and is
currently the only method that can be easily applied to large
population-based studies. Our choice of immunoassay also pro-
vides the opportunity for our results to be compared with those
obtained by others (Hankinson et al, 1999; Tworoger et al, 2004,
2006b, 2007a). Finally, high mammographic density, which is
perhaps the strongest risk factor for non-familial breast cancer
apart from age and gender, has been associated with higher PRL
levels in some (Boyd et al, 2002) but not all (Tamimi et al, 2005;
Johansson et al, 2008) studies. We did not have the ability to
examine the association of PRL levels with mammographic density
in the current analyses.
The strengths of this study include its population-based design,
and extensive collection of risk factor, pathologic and immuno-
histochemical data. Our analyses were based on incident cases
from whom serum was collected at the time of diagnosis of
breast cancer. In addition, PRL measurements have been shown to
be reliable and most likely a reflection of cumulative exposure
over time (Missmer et al, 2006; Arslan et al, 2008; Tworoger and
Hankinson, 2008; Kotsopoulos et al, 2010), and hence can be
considered a stable marker of exposure and potentially risk. We
found that elevated PRL levels were associated with selected breast
cancer risk factors and, with the caveats outlined above, also
increased breast cancer risk among postmenopausal women.
Consistent with previous prospective studies (Tworoger et al,
2004) and case–control studies summarised in a recent review
(Tworoger and Hankinson, 2008), we found that PRL levels were
unrelated to two factors reflecting progression, tumour size, and
lymph node metastases. In conclusion, our data suggest that PRL
levels may be related to several breast cancer risk factors and could
potentially have value in understanding the mechanisms that
mediate these factors. Accordingly, continued study of the
importance of PRL in breast cancer is warranted.
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